-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
RVL Pharmaceuticals plc quarterly/annual Nonoperating Income (Expense) history and change rate from Q3 2017 to Q2 2023.
- RVL Pharmaceuticals plc Nonoperating Income (Expense) for the quarter ending 30 Jun 2023 was $371K, a 376% increase year-over-year.
- RVL Pharmaceuticals plc Nonoperating Income (Expense) for the twelve months ending 30 Jun 2023 was $6.95M, a 39.8% increase year-over-year.
- RVL Pharmaceuticals plc annual Nonoperating Income (Expense) for 2022 was $6.26M.
- RVL Pharmaceuticals plc annual Nonoperating Income (Expense) for 2021 was -$1.33M, a 2677% decline from 2020.
- RVL Pharmaceuticals plc annual Nonoperating Income (Expense) for 2020 was -$48K, a 105% decline from 2019.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)